HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor activity of ME2303, a fluorine-containing anthracycline, against human tumors implanted in nude mice.

Abstract
A fluorine-containing anthracycline, ME2303, given intravenously once a week for 4 weeks at the maximum tolerated doses showed better therapeutic effects against 2 gastric, 3 lung and 2 human breast tumor xenografts than did adriamycin (ADM) at the maximum tolerated dose. Among the tumors, ME2303 showed a better effect against St-40, a well-differentiated human gastric adenocarcinoma, against which ADM showed only a marginal effect. Likewise, ME2303 was more effective against Lu-24 human small cell carcinoma and MX-1 human medullary tubular adenocarcinoma than ADM. Notably, the Lu-24 tumor, developed in nude mice, disappeared after the treatment in 3 out of 6 mice. ME2303 would be an interesting compound for phase I and II clinical studies in the future.
AuthorsT Tsuruo, S Sato, K Yusa
JournalJapanese journal of cancer research : Gann (Jpn J Cancer Res) Vol. 80 Issue 7 Pg. 686-9 (Jul 1989) ISSN: 0910-5050 [Print] Japan
PMID2507492 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ME 2303
  • Doxorubicin
Topics
  • Animals
  • Doxorubicin (analogs & derivatives, therapeutic use)
  • Drug Tolerance
  • Humans
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Neoplasms, Experimental (drug therapy)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: